Yartemlea (narsoplimab-wuug)
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0298 alerts
Get alerted when Policy CC-0298 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity and prior-authorization review of Yartemlea (narsoplimab-wuug) for members with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Coverage is limited to individuals meeting the specified diagnosis, age, laboratory, renal, and exclusion-of-alternative-etiology criteria.
The policy was revised to update the criteria describing when Yartemlea may not be approved.
HCPCS codes C9399 and J3590 were removed from the coding section.
HCPCS code J1289 was added for injection of narsoplimab-wuug, 1 mg.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.